<DOC>
	<DOCNO>NCT01235598</DOCNO>
	<brief_summary>Phase IIIb study determine early response Certolizumab Pegol ( CZP ) Magnetic Resonance Imaging ( MRI ) score Outcome Measures Rheumatoid Arthritis ( RA ) Clinical Trials ( OMERACT ) RA MRI Scoring System ( RAMRIS ) subject RA .</brief_summary>
	<brief_title>Magnetic Resonance Image Verified Early Response Certolizumab Pegol Subjects With Active Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>To identify efficacy Certolizumab Pegol ( CZP ) synovitis dynamic MRI parameter ; make correlation European League Against Rheumatism ( EULAR ) , American College Rheumatology ( ACR ) p , Disease Activity Score-28 ( DAS 28 ) response , Digital XRay ( DXR ) assessment reduction synovitis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects diagnosis adultonset Rheumatoid Arthritis ( RA ) least 3 month duration longer 15 year Subjects active adult Rheumatoid Arthritis disease Subjects DiseaseModifying AntiRheumatic Drug ( DMARD ) therapy least 12 week Subject must secondary , noninflammatory type musculoskeletal condition ( eg , osteoarthritis fibromyalgia ) investigator 's opinion symptomatic enough interfere evaluation effect study drug subject 's primary diagnosis Rheumatoid Arthritis ( RA ) Subject must diagnosis inflammatory arthritis ( eg , psoriatic arthritis ankylose spondylitis ) Subject must history infect joint prosthesis time prosthesis still situ Subject must receive 1 biological agent Subject must history lymphoproliferative disorder include lymphoma sign symptom suggestive lymphoproliferative disease time Subject know Tuberculosis ( TB ) disease , high risk acquire TB infection latent TB infection Subject must know hypersensitivity component investigational medicinal product Subject must contraindications Magnetic Resonance Image ( MRI ) contrast agent Subject must condition , investigator 's judgement , would make unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>CimziaÂ®</keyword>
	<keyword>CDP870</keyword>
	<keyword>CZP</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>MRI</keyword>
</DOC>